Literature DB >> 11406481

Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes.

A D Everett1, T D Stoops, A C Nairn, D Brautigan.   

Abstract

Increased protein synthesis is the cardinal feature of cardiac hypertrophy. We have studied angiotensin II (ANG II)-dependent regulation of eukaryotic elongation factor-2 (eEF-2), an essential component of protein translation required for polypeptide elongation, in rat neonatal cardiac myocytes. eEF2 is fully active in its dephosphorylated state and is inhibited following phosphorylation by eEF2 kinase. ANG II treatment (10(-10) - 10(-7) M) for 30 min produced an AT(1) receptor-specific and concentration- and time-dependent reduction in the phosphorylation of eEF-2. Protein phosphatase 2A (PP2A) inhibitors okadaic acid and fostriecin, but not the PP2B inhibitor FK506, attenuated ANG II-dependent dephosphorylation of eEF-2. ANG II activated mitogen-activated protein kinase, (MAPK) within 10 min of treatment, and blockade of MAPK activation with PD-98059 (1--20 nM) inhibited eEF-2 dephosphorylation. The effect of ANG II on eEF-2 dephosphorylation was also blocked by LY-29004 (1-20 nM), suggesting a role for phosphoinositide 3-kinase, but the mammalian target rapamycin inhibitor rapamycin (10--100 nM) had no effect. Together these results suggest that the ANG II-dependent increase in protein synthesis includes activation of eEF-2 via dephosphorylation by PP2A by a process that involves both PI3K and MAPK.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406481     DOI: 10.1152/ajpheart.2001.281.1.H161

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  10 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats.

Authors:  Ramesh C Gupta; Sudhish Mishra; Xiao-Ping Yang; Hani N Sabbah
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

3.  Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2).

Authors:  Robert T Day; Rita de Cássia Cavaglieri; Hooman Tabatabaimir; Vasudha Mantravadi; Myung-Ja Lee; Jeffrey L Barnes; Balakuntalam S Kasinath; Denis Feliers
Journal:  Cell Signal       Date:  2010-07-24       Impact factor: 4.315

4.  Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt.

Authors:  Anita Y M Chan; Vernon W Dolinsky; Carrie-Lynn M Soltys; Benoit Viollet; Shairaz Baksh; Peter E Light; Jason R B Dyck
Journal:  J Biol Chem       Date:  2008-06-18       Impact factor: 5.157

5.  A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin.

Authors:  Gareth J Browne; Christopher G Proud
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

6.  Interleukin-1β effect on the endogenous ADP-ribosylation and phosphorylation of eukaryotic elongation factor 2.

Authors:  Ebru Hacıosmanoğlu; Başak Varol; Bilge Özerman Edis; Muhammet Bektaş
Journal:  Cytotechnology       Date:  2016-08-10       Impact factor: 2.058

7.  Systematic Analysis Reveals Elongation Factor 2 and α-Enolase as Novel Interaction Partners of AKT2.

Authors:  Katharina Bottermann; Michael Reinartz; Marian Barsoum; Sebastian Kötter; Axel Gödecke
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

8.  PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Authors:  Martina Sj McDermott; Brigid C Browne; Neil T Conlon; Neil A O'Brien; Dennis J Slamon; Michael Henry; Paula Meleady; Martin Clynes; Paul Dowling; John Crown; Norma O'Donovan
Journal:  Mol Cancer       Date:  2014-06-24       Impact factor: 27.401

9.  Coordination of changes in expression and phosphorylation of eukaryotic elongation factor 2 (eEF2) and eEF2 kinase in hypertrophied cardiomyocytes.

Authors:  Satoshi Kameshima; Muneyoshi Okada; Shiro Ikeda; Yuki Watanabe; Hideyuki Yamawaki
Journal:  Biochem Biophys Rep       Date:  2016-06-28

10.  Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line.

Authors:  Meizhi Niu; Manuela Klingler-Hoffmann; Julie A Brazzatti; Briony Forbes; Chareeporn Akekawatchai; Peter Hoffmann; Shaun R McColl
Journal:  Proteome Sci       Date:  2013-01-15       Impact factor: 2.480

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.